Richard Bergstrom, MD
Endocrinology, Diabetes & Metabolism · Portland, ORNPI 1326196841
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.
Across 222 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Abbott$707
- Dexcom, Inc.$589
- Novartis$562
- Pfizer$180
- Novo Nordisk$178
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,59899%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 48 | $1,025 |
| Abbott | 39 | $707 |
| Dexcom, Inc. | 29 | $589 |
| Novartis | 23 | $562 |
| Pfizer | 9 | $180 |
| Novo Nordisk | 9 | $178 |
| Radius Health, Inc. | 8 | $176 |
| Sanofi-aventis U.S. LLC | 7 | $166 |
| Nevro Corp. | 4 | $132 |
| Boehringer Ingelheim | 2 | $123 |
| AstraZeneca(2 entities) | 6 | $108 |
| Corcept Therapeutics | 4 | $91 |
| Lilly USA, LLC | 4 | $89 |
| Zealand Pharma US, Inc. | 6 | $86 |
| Medtronic(2 entities) | 4 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Janssen Scientific Affairs, LLC | 1 | $44 |
| Johnson & Johnson | 2 | $36 |
| Amphastar Pharmaceuticals, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Lifescan, Inc. | 1 | $20 |
| Gilead | 1 | $18 |
| Insulet Corporation | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Echosens North America, Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $12 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
How this compares
$4,646 in reported general payments places this provider in the 70th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 206 | $325,341 |
| JardianceEmpagliflozin | 219 | $294,545 |
| Signifor LarPasireotide Pamoate | 13 | $243,179 |
| MounjaroTirzepatide | 40 | $54,033 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $47,018 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $44,000 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $42,082 |
| Humalog Kwikpen U-100Insulin Lispro | 99 | $40,641 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 177 | $36,799 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $35,854 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $32,439 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $29,165 |
| LyumjevInsulin Lispro-Aabc | 15 | $27,333 |
| HumalogInsulin Lispro | 66 | $27,189 |
| FarxigaDapagliflozin Propanediol | 20 | $25,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $178 | $334,070224 claims |
| Boehringer IngelheimJardiance | $123 | $294,545219 claims |
| Recordati_rare_diseases_inc.Signifor Lar | $16 | $243,17913 claims |
| Lilly USA, LLCMounjaro, Lyumjev, Humalog, Trulicity, Insulin Lispro | $89 | $134,828150 claims |
| AstraZenecaFarxiga | $108 | $25,90420 claims |
| Sanofi-aventis U.S. LLCLantus | $166 | $23,52360 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Portland
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Eric OrwollPortland$94K
- Paul DuellPortland$91K
- Sergio FazioPortland$88K
- Nancy CuroshPortland$59K
- Andrew AhmannPortland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.